PL41 · DCL0029

PL41 evidence summary

Reported PL41-PG formulation

Componentmol%Role
PL4145Ionizable lipid
DSPC9Helper phospholipid
Cholesterol34.65Sterol
DMG-PEG20001.35PEG lipid
DSPG10Anionic TREM2 ligand

Total: 100 mol%. PG denotes 1,2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG). The 5 mol% ligand formulation used PL41:DSPC:cholesterol:DMG-PEG2000:ligand = 47.5:9.5:36.6:1.4:5 mol%. These formulations are distinct from the initial DOPE screening mixture.

Source: Supplementary Table S1 (PDF p. 30 / printed p. 29); main Methods.

Preparation

Microfluidic mixing of aqueous mRNA and ethanol lipid phases at 3:1 by volume. Final mRNA concentration: 0.1 mg/mL. Dialysis overnight at 4 °C against PBS using a 12–14 kDa MWCO membrane. Total mixing flow rate, assembly buffer/pH, N/P and lipid:mRNA mass ratio were not reported in the supplied method.

Source: Methods — Preparation and characterization of LNP formulation (main PDF p. 18).

Experimental evidence

Comparative CAR expression

PL41-PS and PL55-PS were advanced after the healthy-mouse reporter screen (5 µg mRNA per mouse, intraperitoneal, 6 h; n = 5 per group pooled from two experiments). PL41 then gave higher membrane-bound CAR expression than PL55 in mouse BMDM-TAMs and human THP-1-derived M2 macrophages (24 h; n = 3 independent tests).

Source: Main Fig. 2d–g; Supplementary Fig. S6c,d; Methods.

Particle characterization

The tested PL41-PS, PL41-PI and PL41-PG formulations were approximately 150–200 nm and achieved approximately 90% mRNA encapsulation. These ranges describe the tested formulations and are not specifications for neat PL41.

Source: Main text; Supplementary Fig. S6g,h.

TREM2-dependent delivery

In the ligand comparison, the 10 mol% PG formulation gave approximately eightfold higher reporter expression in wild-type than Trem2-knockout macrophages. This comparison is WT versus knockout cells, not PL41 versus ALC-0315.

Source: Main Fig. 2i; main text.

In situ CAR-M and malignant ascites

PL41-PG LNPs delivered hCLDN18.2-targeting CAR mRNA and supported macrophage reprogramming in mouse malignant-ascites models. The study also examined patient-derived ascites ex vivo. Antitumour findings depend on the RNA-loaded formulation, administration schedule, tumour model and, for combination arms, anti-PD-1 treatment.

Source: Main Figs. 3–6; Extended Data; Methods.

Tolerability context

The study evaluated cell viability and mouse tolerability under specified experimental conditions. These preclinical observations do not establish human safety or the safety of other doses, routes or formulations.

Source: Main text and Supplementary Information.

Calculated amount conversion

At M.Wt 1350.22 g/mol, 100 mg = 74.06 µmol and 250 mg = 185.16 µmol. These are amount conversions for planning, not a validated LNP scale-up protocol.

Evidence limits

Values shown are literature-reported results for the cited formulation and study conditions. They do not guarantee performance of the supplied product in other formulations or experiments. Mouse and ex vivo patient-sample results do not establish clinical safety or efficacy. PL41 lipid is supplied separately from DSPG, helper lipids and RNA.

References

Yijia Li, Ting Yang, Xiyue Zhang et al. In situ CAR engineering and nanoparticle-mediated TREM2 degradation for macrophage reprogramming in malignant ascites. Nature Materials (2026). DOI: 10.1038/s41563-026-02769-2. Primary paper.

Structure: main Fig. 2h; Supplementary synthesis pp. 21–22 and Fig. S7. Formulation: Supplementary Table S1. Lead comparisons: Fig. 2 and Supplementary Fig. S6.

Request product documents

For research use only.